Tilray and Curaleaf are reported to dominate the cannabis pharmaceuticals market.
2 reports, 1 independent
Updated Jul 29
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Tilray and Curaleaf are reported to dominate the cannabis pharmaceuticals market.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Tilray
pharmaceutical and cannabis company
-
Curaleaf
Canadian cannabis company
Nothing else this week.
Related events
- Tilray secured a partnership to distribute medical cannabis products in Italy, while Trump's administration considers reclassifying cannabis.
- Aurora Cannabis and Tilray are driving market growth and leading innovations in European cannabis therapies.
- Both Delcath Systems and Curaleaf are facing market scrutiny as healthcare companies.
Coverage
Newest first; wire copies grouped- GlobeNewswireCannabis Pharmaceuticals Market Report 2025-2029 and 2034 Featuring Leading Players - Curaleaf, Aphria, Green Thumb Industries, Trulieve Cannabis Corp, and Tilray This Cannabis Pharmaceuticals market
- GlobeNewswireCannabis-Infused Products Market Analysis Report 2025-2029 and 2034 | E-Commerce Surge Boosting Expansion, SoRSE Emulsion Technology Enhancing Cannabis Beverage Experience The Cannabis-Infused Produc